Oncology Bonanza As Japan Lists New Drugs
This article was originally published in PharmAsia News
Japan has added a total of 22 drug active ingredients to the national health insurance reimbursement tariff, including several novel products for cancer indications that will see their first launches worldwide.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.